<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-112736</identifier>
<setSpec>1134-8046</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:creator>Molà, O</dc:creator>
<dc:creator>Galván, J</dc:creator>
<dc:creator>Tornero, C</dc:creator>
<dc:creator>Herrera, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">This paper summarizes the general characteristics of the opioid system and analgesic mechanisms that have allowed the development of new therapeutic options in the therapy areas of moderate to severe pain of both cancer and noncancer origin. It also summarizes the studies forming together the research program and clinical development (phases I and III) of a new pharmaceutical formulation of buprenorphine transdermal patches, Feliben®, which is compared with other formulations of reference in analgesia. Finally, the current opportunity context that these new formulations have in the management of moderate to severe pain is reviewed (AU)</dc:description>
<dc:source>Rev. Soc. Esp. Dolor;19(6): 301-309, nov.-dic. 2012.</dc:source>
<dc:identifier>ibc-112736</dc:identifier>
<dc:title xml:lang="es">Buprenorfina transdérmica (Feliben®). Nueva opción terapéutica para pacientes con dolor moderado y severo</dc:title>
<dc:subject>^d54692^s22074</dc:subject>
<dc:subject>^d715^s22011</dc:subject>
<dc:subject>^d31907^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d715^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d24852^s22074</dc:subject>
<dc:subject>^d24852^s22045</dc:subject>
<dc:subject>^d2079^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d19054</dc:subject>
<dc:subject>^d54692^s22045</dc:subject>
<dc:subject>^d28622^s22045</dc:subject>
<dc:subject>^d54692^s22066</dc:subject>
<dc:type>article</dc:type>
<dc:date>201212</dc:date>
</metadata>
</record>
</ibecs-document>
